Three Weill Cornell Medicine scientists were honored this week with the Presidential Early Career Award for Scientists and Engineers, the U.S. government’s highest commendation for outstanding early-career scientists and engineers.
January 2025 EIPM Director's Memo
January 1, 2025
Dear Members of the Englander Institute,
I hope everyone enjoyed the holiday season had a chance to reconnect with family and friends, and refresh yourselves for the year ahead.
EIPM's Fourth Quarter 2024 External Newsletter!
December 31, 2024
EIPM's Fourth Quarter 2024 External Newsletter
December 31, 2024
Putting the Brakes on Prostate Cancer Cells
December 16, 2024
Prostate cancer hijacks the normal prostate’s growth regulation program to release the brakes and grow freely, according to Weill Cornell Medicine researchers. The discovery, published Dec. 13 in Nature Communications, paves the way for new diagnostic tests to guide treatment and could also help drug developers identify novel ways to stop the disease.
Finding Innovative Ways to Address Kidney Cancer Leads to DoD Grant
December 10, 2024
Weill Cornell Medicine has received a $1.4 million, four-year grant from the U.S. Department of Defense to investigate a new therapeutic approach for the most common form of kidney cancer.
Landmark AI Project Harnesses Voice to Diagnose Disease, Releases First Data
December 2, 2024
Researchers at USF Health and Weill Cornell Medicine, as part of an expansive, multi-institutional project investigating voice as a biomarker for disease, have reached a significant milestone by publishing the first version of their clinically validated voice dataset to an online artificial intelligence platform where it will be an invaluable resource for researchers across the globe.
Study Unveils Key Strategies Against Drug-Resistant Prostate Cancer
November 20, 2024
An enzyme called EZH2 has an unexpected role in driving aggressive tumor growth in treatment-resistant prostate cancers, according to a new study by scientists at Weill Cornell Medicine. The results could potentially lead to new therapies for patients with limited options and add to the significant progress the teams have made in understanding how advanced prostate cancer develops resistance to treatments that target androgen receptors.
Metabolic Reprogramming of T cells May Enhance Checkpoint Inhibitor Therapy
November 4, 2024
Stimulating a key metabolic pathway in T cells can make them work more effectively against tumors when combined with immune checkpoint inhibitor therapy, according to a preclinical study led by researchers at Weill Cornell Medicine. The findings suggest a potential strategy for enhancing the potency of anticancer immunotherapies.
Dr. Ekta Khurana Wins New Starr Cancer Consortium Grant!
October 29, 2024
New Starr Cancer Consortium Grants Awarded to Weill Cornell Medicine Researchers
October 30, 2024
Three teams led by Weill Cornell Medicine scientists have received awards from the Starr Cancer Consortium in its 17th and final annual grant competition. The grants will fund research on the deep mechanisms of common cancers and related treatment strategies.